Preclinical models play an essential role in vaccine development, serving as the first step in evaluating a vaccine’s safety and effectiveness before human clinical trials. These models often involve the use of animals, such as mice or primates, to simulate how the vaccine will behave in humans. By studying how the immune system responds to the vaccine in these animals, researchers can assess key factors such as immune activation, potential side effects, and the optimal dosage. The data gathered from preclinical studies provide crucial insights that guide the design of human clinical trials. Advances in immune system modeling and genetic engineering have made preclinical models more accurate and predictive, reducing the chances of failure in later-stage trials. These models are instrumental in identifying promising vaccine candidates for diseases like cancer, HIV, or malaria, and are continually refined to ensure they closely mimic human responses to vaccinations.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States